Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis C (MBL-HCV1)
Open-Label, Dose Escalation Phase I Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (MBL-HCV1) Against Hepatitis C E2 Glycoprotein
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- DaVita Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Study subject must have read, understood and provided written informed consent and HIPAA authorization after the nature of the study has been fully explained.
- Be > or equal to 18 years of age and < or equal to 55 years of age.
- Be in general good health without history of any of the conditions listed in exclusion criteria.
- No use of any tobacco products for at least 6 months.
- A woman must agree not to become pregnant from the time of study enrollment until at least 3 months after the completion of the monoclonal antibody infusion. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel.
- Sexually active male subjects must use a barrier method of contraception during the course of the study.
Screening laboratory values must meet the following criteria:
- WBC (>3,900 - <11,000/mm^3)
- Platelets(>100,000/mm^3)
- Hemoglobin (>10.5 gm/dl)
- Creatinine (<1.1 x ULN)
- BUN (<1.25 x ULN)
- AST(<1.1 x ULN)
- ALT (<1.1 x ULN)
- Alkaline Phosphatase (<1.1 x ULN)
- Bilirubin (<1.1 x ULN)
- Glucose-nonfasting (>/=60 mg/dl and </=115 mg/dl)
Exclusion Criteria:
- Previous receipt of humanized or human monoclonal antibody whether licensed or investigational.
- Weight >90 kg
History of any of the following illnesses or conditions:
- Cancer
- Heart Disease
- Diabetes mellitus
- Respiratory condition (such as asthma requiring daily medication)
- Autoimmune disorder
- Blood dyscrasias
- Psychiatric disorder that precludes compliance with protocol
- Hepatitis
- Any chronic condition requiring daily prescription or over-the-counter medicine except for vitamins and birth control products.
- Drug or alcohol abuse within previous 12 months or a positive screen within 24 hours of monoclonal antibody administration.
- History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
- Physical finding on examination considered clinically significant such as murmur (other than functional), hepatosplenomegaly, lymphadenopathy or focal neurological deficit.
- Systolic blood pressure >140 or < 90 and/or diastolic blood pressure >90 on two separate readings.
- Urinalysis positive for > trace protein, >5 rbc/hpf or >5 wbc/hpf
- Positive serology for HIV antibody, HCV antibody or Hepatitis B surface antigen.
- Positive urine pregnancy test during screening or within 24 hours of monoclonal antibody administration, or an unwillingness to undergo pregnancy testing.
- Breast-feeding.
- Receipt of licensed vaccine or other investigational study agent within previous 30 days.
- Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: MBL-HCV1
|
Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assess safety and tolerability of escalating doses of a human monoclonal antibody against Hepatitis C E2 glycoprotein (MBL-HCV1) in healthy adults.
Time Frame: 56 days
|
56 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determine pharmacokinetics of a human monoclonal antibody against Hepatitis C E2 glycoprotein (MBL-HCV1) given as a single intravenous infusion.
Time Frame: 56 days
|
56 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suzanne Swan, MD, DaVita Clinical Research
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA-HCV1-09-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.